Hybrids VITA, developed together with Medical Simulator, reproduces different clinical scenarios for training on how to prevent, diagnose and treat possible complications of ECMO, which is a very complex technique.

The device, called Winco USG, is a simulation platform for holistic and integrated training of professionals performing this type of procedure.

The Biomedical Research in Cancer Stem Cells group at VHIR has identified a new therapeutic target and is working to find new therapies for this type of tumor.

VHIR organises the first meeting between entrepreneurs and the investment ecosystem.

A clinical trial with the prototype of the device shows that the use of this technology improves patient monitoring by nurses and reduces post-surgical complications.

The second Joan Roget Awards for Knowledge Transfer acknowledged three success stories in the Catalan research system, including the VHIR for the creation of its own innovation model.

The product is now in the last stage of prototyping and will move to the verification and validation stages thanks to current fundraising.

This collaboration solidifies their co-ownership of the patent application for "markers for the diagnosis of large vessel occlusion"

This investment from EIT Health in the project will enable D-Sight to progress in the clinical development of its groundbreaking treatment for the early stages of diabetic retinopathy.

After carrying out a first feasibility trial in collaboration with the Assisted Reproduction Section of the Vall d'Hebron Hospital, Manina Medtech is moving towards a pilot trial in IVF patients.

This initiative of the ”la Caixa” Foundation offers the selected entrepreneurial scientists financial support and support through individual mentoring and training.

The head of the Rheumatology Service at Vall d'Hebron University Hospital and of the Rheumatology research group at VHIR is a highly accomplished rheumatologist with a distinguished career in the field.

Femtech is a spin-off of the Vall d'Hebron Research Institute (VHIR) and is part of the accelerator BCN Health Booster of the Barcelona Science Park

YSOTOPE, a DeepTech start-up with the mission to improve the use of immunotherapies through medical imaging, became part of the spin-off network of VHIR and successfully closed its first investment round of €150,000 with Biozell Ventures.

The start-up Tesai Care works in developing Heecap, a non-invasive electrostimulation system to avoid atrophy to the muscles of respiration in patients on mechanical ventilation in ICUs.

The investment will enable D-Sight to progress with the first phase of clinical validation of their drug for early-stage diabetic retinopathy and glaucoma.

With this agreement, the Hospital and the Vall d’Hebron Research Institute (VHIR) has officially become a part of the Barcelona Health Hub ecosystem, providing them with an opportunity to connect with leading digital health players across the globe.

The goal is to test a low-cost, easy-to-use and non-invasive monitor, which will serve to control intracranial pressure (PICO) values, which will help to control and treat different acute brain pathologies.

This new technology provides image quality currently unavailable with paediatric and neonatal transoesophageal probes, offering an exact correlation between the real-time 3D heart image and the paediatric patient’s anatomy.

Els premiats són un projecte de simulació per entrenar-se en maneig d'ECMO, un programa d’entrenament de treball en equip amb simulació i una base de dades que permet registre i consulta del procés de donació d'òrgans i teixits en temps real.

The Barcelona Aging coLLaboratory (BALL) aims to create innovative solutions, with the participation of end users, to improve quality of life and health and social care for the elderly.

El concurs Jo Innovo posa punt final a cinc dies plens d’activitats amb la recerca, l’emprenedoria, la transformació digital, la simulació i la robòtica com a protagonistes.

The different members of the network met in Vall d’Hebron to share their innovations processes, needs, challenges, and goals

Manina Medtech received a direct grant of 75,000 euros from the ACCIÓ Startup Capital line, aimed at boosting the growth of emerging companies with high technological potential.